ezetimibe has been researched along with spironolactone in 4 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 7,222 | 960 | 1,923 |
| Protein | Taxonomy | ezetimibe (IC50) | spironolactone (IC50) |
|---|---|---|---|
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Estrogen receptor | Homo sapiens (human) | 5.702 | |
| Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
| Progesterone receptor | Homo sapiens (human) | 1.675 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
| Androgen receptor | Homo sapiens (human) | 0.3585 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for ezetimibe and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for ezetimibe and spironolactone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Avoid the risks of mixed medications. How to minimize dangerous interactions with cardiovascular drugs.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Drug Interactions; Eplerenone; Ezetimibe; Fluorobenzenes; Humans; Polypharmacy; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Sulfonamides | 2003 |